The drugmaker expects the two treatments, Skyrizi and Rinvoq, to bring in a combined revenue of about $1.70 billion in 2020. The profit forecast excludes any impact from its $63 billion deal for Botox-maker Allergan Plc , which it expects to close in the first quarter. “The launches of Skyrizi and Rinvoq are going extremely well,” Chief Executive Officer Richard Gonzalez said in a statement. …read more
Source:: Yahoo Finance
